BlueWillow Biologics® today announced the company has been awarded an NIH Small Business Innovation Research (SBIR) grant for the development of an intranasal NanoVax® vaccine for the prevention of chlamydia.
BlueWillow announces the issuance of a patent to the University of Michigan, under exclusive license to BlueWillow, which allows use of BlueWillow’s NanoVax® platform with tumor antigens to create novel therapeutic vaccines that could potentially generate immune responses to treat existing cancers.
NanoBio Corporation, a clinical-stage biopharmaceutical company, today announced that it has changed its corporate name to BlueWillow Biologics® in conjunction with the closing of a $10 million Series A financing. The financing round was led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.
University of Michigan Researchers Show Intranasal NanoVax Vaccination Suppresses Peanut Allergies in Mice
BlueWillow’s intranasal NanoVax vaccination protected mice from allergic reactions when exposed to peanut, according to U-M researchers.
NanoBio Corporation today announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by the U.S. National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
NanoBio Corporation today announced that it has been awarded a two-year Phase II Small Business Research Innovation (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development of an intranasal nanoemulsion (NE) adjuvanted vaccine for the prevention of genital herpes.
NanoBio Corporation today announced the issuance of a patent which broadly covers the composition of NanoBio’s intramuscular and intranasal RSV vaccine candidates, combining the company’s innovative nanoemulsion (NE) adjuvant with strain L19 of RSV.
NanoBio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting
NanoBio Corporation today announced that the company will present key data at the Mucosal Immunology Course & Symposium Meeting (MICS) in Toronto, demonstrating the advantages of its intranasal nanoemulsion (NE) adjuvant for use in the development of vaccines for pertussis.
NanoBio to Present Data Demonstrating Benefit of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine
NanoBio Corporation will present key data demonstrating the advantages of its nanoemulsion (NE) adjuvant for use in the development of intramuscular vaccines for pandemic influenza and other diseases,at the GTCbio 14th Vaccines Research & Development Conference on June 3, 2016.
NanoBio’s Genital Herpes Vaccine Demonstrates Efficacy in Guinea Pigs as Both a Prophylactic and a Therapeutic Vaccine
NanoBio Corporation today announced that its intranasal nanoemulsion (NE) adjuvanted genital herpes vaccine has demonstrated efficacy in studies conducted in both the prophylactic and the therapeutic guinea pig model. The data was recently presented at the 40th Annual International Herpesvirus Workshop in Boise, ID.
NanoBio to Present Data Demonstrating the Potential for its Intranasal Vaccine to Protect Against Genital Herpes Infection
NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014. The Company’s presentation will highlight the advantages of its nanoemulsion (NE) adjuvant in the development of a prophylactic genital herpes vaccine that induces protection by eliciting both systemic and mucosal immune responses.
ANN ARBOR, Mich., (April 28, 2014) – NanoBio Corporation today announced that the company will present new data at the National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (NFID ACVR ), demonstrating the benefits of its nanoemulsion (NE) adjuvant in the development of an intranasal herpes simplex virus-2 (HSV-2) vaccine.
Additional funding allocated to research nanoemulsion-adjuvanted HIV vaccine ANN ARBOR, Mich., (October 29, 2013) – NanoBio Corporation today announced that the company has been awarded an initial contract worth $5.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a nanoemulsion (NE) adjuvant […]
NanoBio to Present Data at ICAAC Supporting the Development of Safe and Effective RSV and Herpes Simplex Virus-2 Vaccines
Pre-clinical data demonstrates the ability of nanoemulsion-adjuvanted vaccines to provide immunogenicity and protection against illness and disease ANN ARBOR, Mich., (September 11, 2013) – NanoBio Corporation today announced that the company will present new data at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting showing the safety and efficacy of a nanoemulsion […]
NanoBio’s Novel NanoStat Technology Demonstrates Significant Effectiveness as Intramuscular Vaccine Adjuvant
New data unveiled at NFID 2013 shows that intramuscular administration of NE-RSV vaccine to cotton rats delivers robust immunogenicity, high neutralizing antibodies, protection without enhanced disease ANN ARBOR, Mich., (April 23, 2013) – NanoBio Corporation today announced that the company will present new data demonstrating positive pre-clinical results for its intramuscular (IM) respiratory syncytial virus […]
NanoBio and the U.K. Health Protection Agency Awarded Up to $24 Million to Develop an Intranasal Anthrax Vaccine
ANN ARBOR, Mich. (December 1, 2012) – NanoBio® Corporation announced today that it is partnering with the U.K.-based Health Protection Agency (HPA) to develop an intranasal anthrax vaccine for the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
Funds Will Support Ongoing Clinical and Preclinical Development Programs ANN ARBOR, Mich. (November 28, 2012) – NanoBio Corporation announced today the closing of an $11 million Series C financing, including full participation from its existing investor syndicate. Proceeds from the financing will be used to advance the company’s development programs for herpes labialis (cold sores), […]
ANN ARBOR, Mich. and SAN DIEGO (October 15, 2012) – NanoBio Corporation announced today that results from its nanoemulsion adjuvanted RSV vaccine will be presented at IDWeek 2012™ taking place from Oct. 17-21 in San Diego.
ANN ARBOR, Mich. (October 9, 2012) – NanoBio® Corporation today announced the promotion of David Peralta to chief executive officer. Mr. Peralta, who previously served as the company’s chief operating and financial officer, replaces James R. Baker, Jr. M.D., who recently joined Merck & Co. as the senior vice president, head global vaccine franchise. As […]
NanoBio to Report Data on Its Nanoemulsion Adjuvanted Intranasal RSV Vaccine at the 8th Annual International Respiratory Syncytial Virus Symposium
ANN ARBOR, Mich. and SANTA FE, N.M. (September 24, 2012) – NanoBio® Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.